BN

Boris Nikolic

North America, Massachusetts, United States, Boston

Description

Boris Nikolic is the Board Member of Schrodinger.

Dr. Boris Nikolic is a Scientific Advisor to Bill Gates at Bill Gates Catalyst 3 (bgc3)...

Investor Profile

Boris Nikolic has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 50% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series D rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Genetics.

Stage Focus

  • Series B (50%)
  • Series D (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Genetics
  • Medical
  • Chemical
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Boris Nikolic frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 1
Alexandria
North America, California, United States, San Francisco
Co-Investments: 1
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 1
Deerfield
North America, New York, United States, New York
Co-Investments: 1
Innova Capital
South America, Sao Paulo, Brazil, São Paulo
Co-Investments: 1
Jennison Associates
North America, New York, United States, New York
Co-Investments: 1
CI
North America, New York, United States, New York
Co-Investments: 1
Flagship Pioneering
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 2

What are some of recent deals done by Boris Nikolic?

Twist Bioscience

San Francisco, California, United States

Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.

BiotechnologyChemicalHealth CareLife Science
Series DJan 19, 2016
Amount Raised: $61,000,000
Editas Medicine

Cambridge, Massachusetts, United States

Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.

BiotechnologyGeneticsHealth CareMedical
Series BAug 10, 2015
Amount Raised: $120,000,000